Cardiovascular Diseases Clinical Trial
Official title:
ENDOBARC-S Study: "Endovascular Branched Stent-grafts for Aortic ARCh Pathologies in Spain"
NCT number | NCT05309707 |
Other study ID # | 2022-03 |
Secondary ID | |
Status | Recruiting |
Phase | |
First received | |
Last updated | |
Start date | January 1, 2022 |
Est. completion date | December 31, 2027 |
The ENDOBARC-S post-market clinical follow-up study is undertaken to evaluate the prevention of death related to aortic arch pathologies when treated by branch stent graft systems (Nexus stent-graft system®, Relay Branch® or Zenith arch branch graft®), with proximal landing at zone 0. The secondary objective is to evaluate the safety and clinical performance of the studied devices.
Status | Recruiting |
Enrollment | 100 |
Est. completion date | December 31, 2027 |
Est. primary completion date | January 1, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 90 Years |
Eligibility | Inclusion Criteria: - Patient is between 18 and 90 years old - Patient with aortic arch pathologies (aneurysm, pseudoaneurysm, dissection, penetrating ulcer, intramural hematoma), treated by branched stent-grafts (Nexus stent graft system©, Relay® Branch or Zenith arch branch graft®, with proximal landing at zone 0. - Patient must be available for the appropriate follow-up times for the duration of the study - Informed consent signed. Exclusion Criteria: - Patient less than 18 years old or more than 90 years old. - Patient has allergies to materials necessary for endovascular repair (e.g. contrast media, anticoagulants or heparin, nitinol, polyester, gold, platinum-iridium) - Patient has systemic infection or suspected systemic infection - Patient has thrombocytopenia (platelet count < 150000/µl) - Patient has untreated hyperthyroidism - Patient has a progressive or untreated malignancy. - Patient is pregnant or breastfeeding. - Patient has a life expectancy of less than 1 year. - Not informed consent signed |
Country | Name | City | State |
---|---|---|---|
Spain | Spanish society for Angiology and Vascular Surgery | Madrid |
Lead Sponsor | Collaborator |
---|---|
Vascular Investigation Network Spanish Society for Angiology and Vascular Surgery |
Spain,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Mortality | Rate of all-cause mortality | 30 days | |
Secondary | Mortality | Rate of all-cause mortality in peri-operative periods (all related interventions) | 24 hours | |
Secondary | Mortality | Rate of all-cause mortality | 3-6, 12, 24, 36, 48, 60 months | |
Secondary | Rupture | Rate of patients with aneurysm rupture | 3-6, 12, 24, 36, 48, 60 months | |
Secondary | Major Adverse Events (MAE) | Rate of patients with major adverse events (aneurysm related death, aneurysm rupture, new myocardial infarction requiring intervention (percutaneous transluminal coronary angioplasty, bypass), new disabling stroke, visceral ischemia (bowel ischemia with surgery or submission to ICU or bowel necrosis with surgery or submission to ICU), new hepatic infarction, new chronic renal insufficiency/renal failure requiring dialysis, new permanent paraplegia, new permanent paraparesis, lower limb ischemia (increase in Rutherford classification) (product-related, procedure-related, aneurysm-related) | prior to discharge, 30 days, 3-6, 12, 24, 36, 48, 60 months | |
Secondary | Number of interventions | Rate of interventions in peri-operative periods (all related interventions until index procedure) | Perioperative | |
Secondary | Delivery time | Rate of time intervals the branched-stent graft implantation | Perioperative | |
Secondary | Reintervention | Rate of reinterventions | 30 days, 3-6, 12, 24, 36, 48, 60 months | |
Secondary | Endoleak | Rate of patients with endoleak | 30 days, 3-6, 12, 24, 36, 48, 60 months | |
Secondary | Proximal intercomponent separation | Rate of patients with intercomponent separation at the proximal end of the Nexus stent-graft system > 10 mm | 30 days, 3-6, 12, 24, 36, 48, 60 months | |
Secondary | Integrity | Rate of patients with loss of device integrity (stent fracture and tear in graft material and suture break) | 30 days, 3-6, 12, 24, 36, 48, 60 months | |
Secondary | Kinking | Rate of patients with stent graft or bridging stent graft kinking | 30 days, 3-6, 12, 24, 36, 48, 60 months | |
Secondary | Primary patency | Rate of primary patency of bridging stents | 30 days, 3-6, 12, 24, 36, 48, 60 months | |
Secondary | Secondary patency | Rate of secondary patency of bridging stents | 30 days, 3-6, 12, 24, 36, 48, 60 months | |
Secondary | Infection | Rate of patients with stent graft infection | 30 days, 3-6, 12, 24, 36, 48, 60 months | |
Secondary | Primary technical success | Rate of patients with primary technical success. Technical success is achieved in case all above mentioned criteria are fulfilled, however, an additional unplanned endovascular or surgical procedure is necessitated within 24 h after the index procedure.
Successful introduction and deployment of the multibranch stent-graft systems in the absence of: Surgical conversion Mortality Reintervention Unplanned branch vessel occlusion (post-operative occlusion) Including: Secure proximal and distal fixation Patent treated branch vessels |
24 hours | |
Secondary | Technical success | Rate of patients with technical success. Technical success is achieved in case all above mentioned criteria are fulfilled, however, an additional unplanned endovascular or surgical procedure is necessitated after the index procedure. | 24 hours | |
Secondary | Primary clinical success | Rate of patients with primary clinical success.
Primary clinical success is reported on an intent-to-treat basis and is reached if the following criteria are fulfilled at the time of follow-up starting at 12 months follow-up: Successful deployment of the endovascular devices at the intended location in the absence of: Death as result of aneurysm-related treatment Conversion to open repair Reintervention after index procedure Occlusion of treated branch vessels Type I or III endoleak Increasing aneurysm size Aneurysm rupture |
30 days, 3-6, 12, 24, 36, 48, 60 months | |
Secondary | Clinical success | Rate of patients with clinical success. Clinical success is achieved in case all above mentioned criteria are fulfilled, however, an additional unplanned endovascular or surgical procedure is necessitated after the index procedure. | 30 days, 3-6, 12, 24, 36, 48, 60 months | |
Secondary | Stable aneurysm size | Rate of patients with stable aneurysm size | 30 days, 3-6, 12, 24, 36, 48, 60 months | |
Secondary | Decreasing | Rate of patients with decreasing (<5mm) aneurysm size | 30 days, 3-6, 12, 24, 36, 48, 60 months | |
Secondary | Increasing | Rate of patients with increasing (>5mm) aneurysm size | 30 days, 3-6, 12, 24, 36, 48, 60 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05654272 -
Development of CIRC Technologies
|
||
Recruiting |
NCT05650307 -
CV Imaging of Metabolic Interventions
|
||
Recruiting |
NCT04515303 -
Digital Intervention Participation in DASH
|
||
Completed |
NCT04056208 -
Pistachios Blood Sugar Control, Heart and Gut Health
|
Phase 2 | |
Recruiting |
NCT04417387 -
The Genetics and Vascular Health Check Study (GENVASC) Aims to Help Determine Whether Gathering Genetic Information Can Improve the Prediction of Risk of Coronary Artery Disease (CAD)
|
||
Not yet recruiting |
NCT06211361 -
Cardiac Rehabilitation Program in Patients With Cardiovascular Disease
|
N/A | |
Not yet recruiting |
NCT06032572 -
Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE)
|
N/A | |
Recruiting |
NCT04514445 -
The BRAVE Study- The Identification of Genetic Variants Associated With Bicuspid Aortic Valve Using a Combination of Case-control and Family-based Approaches.
|
||
Enrolling by invitation |
NCT04253054 -
Chinese Multi-provincial Cohort Study-Beijing Project
|
||
Completed |
NCT03273972 -
INvestigating the Lowest Threshold of Vascular bENefits From LDL Lowering With a PCSK9 InhibiTor in healthY Volunteers
|
N/A | |
Completed |
NCT03680638 -
The Effect of Antioxidants on Skin Blood Flow During Local Heating
|
Phase 1 | |
Recruiting |
NCT04843891 -
Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis.
|
Phase 1 | |
Completed |
NCT04083872 -
Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of Highdose CKD-385 in Healthy Volunteers(Fasting)
|
Phase 1 | |
Completed |
NCT04083846 -
Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of High-dose CKD-385 in Healthy Volunteers(Fed)
|
Phase 1 | |
Completed |
NCT03693365 -
Fluid Responsiveness Tested by the Effective Pulmonary Blood Flow During a Positive End-expiratory Trial
|
||
Completed |
NCT03619148 -
The Incidence of Respiratory Symptoms Associated With the Use of HFNO
|
N/A | |
Completed |
NCT03466333 -
Postnatal Enalapril to Improve Cardiovascular fUnction Following Preterm Pre-eclampsia
|
Phase 2 | |
Completed |
NCT04082585 -
Total Health Improvement Program Research Project
|
||
Completed |
NCT05132998 -
Impact of a Comprehensive Cardiac Rehabilitation Program Framework Among High Cardiovascular Risk Cancer Survivors
|
N/A | |
Completed |
NCT05067114 -
Solutions for Atrial Fibrillation Edvocacy (SAFE)
|